Inflammasomes and Pyroptosis as Therapeutic Targets for COVID-19 | Zendy

Jeremy Kean Yi Yap | Zendy; Miyu Moriyama | Zendy; Akiko Iwasaki | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Inflammasomes and Pyroptosis as Therapeutic Targets for COVID-19

Author(s) -

Jeremy Kean Yi Yap,

Miyu Moriyama,

Akiko Iwasaki

Publication year - 2020

Publication title -

the journal of immunology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.737

H-Index - 372

eISSN - 1550-6606

pISSN - 0022-1767

DOI - 10.4049/jimmunol.2000513

Subject(s) - pyroptosis , inflammasome , coronavirus , innate immune system , immunology , covid-19 , medicine , immune system , disease , inflammation , infectious disease (medical specialty)

The inflammatory response to severe acute respiratory syndrome-related coronavirus 2 infection has a direct impact on the clinical outcomes of coronavirus disease 2019 patients. Of the many innate immune pathways that are engaged by severe acute respiratory syndrome-related coronavirus 2, we highlight the importance of the inflammasome pathway. We discuss available pharmaceutical agents that target a critical component of inflammasome activation, signaling leading to cellular pyroptosis, and the downstream cytokines as a promising target for the treatment of severe coronavirus disease 2019-associated diseases.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research